Research & Development
Micronoma receives FDA breakthrough device designation for liquid biopsy assay to detect lung carcinoma
The company noted that as a result of the designation, it can expect continued guidance and prioritized reviews from the agency of an upcoming clinical trial, part of a process aimed at obtaining a pre-market approval.
January 11, 2023
Argus Research initiates coverage of BioAffinity Technologies at $9 per share
BioAffinity's CyPath Lung lab-developed test uses flow cytometry and machine-learning algorithms to profile the approximately 20 million cells in an average sputum sample in less than 20 minutes.
December 19, 2022
University of Louisville developing experimental approach for lung cancer breath test
A research group is leveraging measurements of volatile organic compounds and machine learning to develop a test that detects lung cancer.
December 2, 2022
Chest publication suggests potential for MagArray blood test to stratify lung cancer risk
Its Knodule ID test is a multianalyte assay with algorithmic analysis comprising seven protein biomarkers and six clinical factors.
November 21, 2022
Biofidelity developing assay for single-molecule detection of multiple gene fusions
The firm said its assay analyzes DNA and RNA concurrently from a single patient sample and can return results within two days.
October 18, 2022
Delfi tapped for European lung cancer screening study
The trial will explore how often people should get screened for lung cancer if their initial CT exam is negative; Delfi's liquid biopsy testing will help investigators assess whether study participants could benefit from a screening CT exam. The trial is being conducted via a partnership with the Netherlands Cancer Institute (NKI) and the institute for DiagNostic Accuracy (iDNA). Delfi will work with the first 9,000 study participants enrolled in the trial through the NKI and Gustave Roussy in Villejuif, France, it said.
September 11, 2022
OncoCyte nabs five-year supply contract for lung cancer test
A molecular stratification test, DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.
August 30, 2022
Guardant expands use of liquid biopsy test to breast, lung cancer
Guardant Reveal identifies circulating tumor DNA in blood as soon as three weeks after surgery and eliminates the need for a tissue biopsy, the company said.
August 14, 2022
Gene analysis sees success in cancer treatment study
In research presented Sunday at the International Association for the Study of Lung Cancer (IASLC) meeting in Vienna, a team led by Dr. Kei Morikawa of St. Marianna University School of Medicine in Kawasaki, Japan, has found that gene analysis using cytological specimens had a high success rate and that the yield and quality of extracted nucleic acid were adequate for panel analysis.
August 7, 2022
Guardant Health highlights clinical results at IASLC
A study that used Guardant's GuardantInform database analyzed information from more than 2,000 patients with any EGFR mutation who had undergone osimertinib therapy, as well as outcomes from this therapy up to five years after it began. It showed a 12.5% incidence of the mutation in lung cancer patients unlikely to respond to the treatment, the company said.
August 7, 2022
Foundation Medicine highlights lung cancer study results
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
August 7, 2022
Biodesix touts VeriStrat test results
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
July 19, 2022
Page 1 of 6